Syndax Pharmaceuticals (SNDX)
20.56
-0.12 (0.58%)
Upcoming Events
Latest Headlines
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 4, 2026 4:01 PM - StreetInsider
Syndax Announces Participation in September Investor Conferences
September 1, 2026 7:00 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
August 21, 2026 7:39 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at JPMorgan
August 11, 2026 8:49 AM - StreetInsider
Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP
August 7, 2026 11:00 AM - SEC Filing
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 5, 2026 4:01 PM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $38 at H.C. Wainwright
August 5, 2026 6:37 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at BofA Securities
August 5, 2026 5:08 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) Misses Q2 EPS by 7c
August 4, 2026 4:10 PM - StreetInsider
Form 10-Q Syndax Pharmaceuticals For: Jun 30
August 4, 2026 4:05 PM - SEC Filing
Form 8-K Syndax Pharmaceuticals For: Aug 04
August 4, 2026 4:03 PM - SEC Filing
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 4, 2026 4:01 PM - StreetInsider
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
July 15, 2026 7:38 AM - StreetInsider
Form 8-K Syndax Pharmaceuticals For: Jul 14
July 14, 2026 8:31 AM - SEC Filing
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026 8:00 AM - Globe NewsWire
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026 8:00 AM - StreetInsider
Form 4 Syndax Pharmaceuticals For: Jul 08 Filed by: Metzger Michael A
July 9, 2026 4:54 PM - SEC Filing
Form 144 Syndax Pharmaceuticals Filed by: Metzger Michael A
July 8, 2026 4:39 PM - SEC Filing
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 1, 2026 4:01 PM - StreetInsider
Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
June 15, 2026 9:32 AM - StreetInsider
Form 4 Syndax Pharmaceuticals For: Jun 11 Filed by: Botwood Nicholas A.J.
June 12, 2026 5:10 PM - SEC Filing
Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.
June 12, 2026 4:11 PM - SEC Filing
Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Guggenheim
June 12, 2026 6:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
June 12, 2026 6:53 AM - StreetInsider
Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.
June 11, 2026 4:13 PM - SEC Filing
Syndax presents Revuforj clinical data across acute leukemia subtypes
June 11, 2026 7:03 AM - StreetInsider
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026 7:03 AM - StreetInsider
Syndax publishes SAVE trial data on Revuforj combination therapy in AML
June 11, 2026 7:02 AM - StreetInsider
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl
June 11, 2026 7:00 AM - StreetInsider
Syndax raises $250 million through convertible notes offering
June 10, 2026 5:08 PM - StreetInsider
Form 8-K Syndax Pharmaceuticals For: Jun 10
June 10, 2026 5:05 PM - SEC Filing
Form 8-K Syndax Pharmaceuticals For: Jun 10
June 10, 2026 4:16 PM - SEC Filing
Full Article List
